More recently, focus has switched to pTau217, i.e. tau phosphorylated at amino acid 217, which appears to discriminate better between individuals with AD pathology and controls due to a larger fold-change between the groups compared to pTau1818. This evidence concerns the gene MAPT and Alzheimer disease.